MoFo Life Sciences

November 03, 2020 - Licensing + Commercial, FDA, COVID-19, Intellectual Property
Podcast: Toward a Vaccine for COVID-19: The Science and Legal Considerations
By: Otis Littlefield and Michael R. Ward
In this third of a four-part podcast series, we discuss the science, regulatory framework, and commercial transactions considerations of a COVID-19 vaccine. Michael Ward, MoFo partner and global head of the firm’s Life Sciences Group and Patent Group, discusses these issues among others with:
... ›
October 22, 2020 - AI + Robotics, Licensing + Commercial, FDA, COVID-19, Intellectual Property, Privacy + Data Security
Podcast: Applying AI and Data Science to the Fight Against COVID-19: The Science and Legal Considerations
By: Jean Nguyen, Kristen J. Mathews, Matthew Karlyn and Michael R. Ward
In this second of a four-part podcast series on the science, regulatory framework, commercial transactions, and privacy and data security considerations of each unique aspect of the current health crisis, Michael Ward, MoFo partner and global head of the firm’s Life Sciences Group and
... ›
October 13, 2020 - Licensing + Commercial, FDA, COVID-19, Intellectual Property, Privacy + Data Security
Podcast: Unpacking the Science and Legal Considerations of COVID-19 Testing
By: Matthew Karlyn, Kristen J. Mathews and Michael R. Ward
In this first of a four-part podcast series on the science, regulatory framework, commercial transactions, and privacy and data security considerations of each unique aspect of the current health crisis, Michael Ward, MoFo partner and global head of the firm’s Life Sciences Group and
... ›
October 07, 2020 - United States, FDA, Litigation, Intellectual Property
Navigating The CRISPR Patent Landscape and Understanding The FDA and its Process
By: Michael R. Ward
“What can be a better day to talk about the complex CRISPR/Cas9 patent landscape than the big day that the Nobel Prize was awarded to pioneers of this revolutionary technology? The story of the continuing dispute on the fundamental CRISPR/Cas9 patents offers a lot
... ›
October 01, 2020 - AI + Robotics, United States, Intellectual Property
Special Patents and AI with Janet Xiao and Anna Yuan
By: Janet Xiao, Anna Yuan and Michael R. Ward
In this third installment of a six-part Patent Law Course offered by Morrison & Foerster and GSAS Harvard Biotech Club , MoFo partner and head of the firm’s China Life Sciences Group Janet Xiao taught a class on the value, protection, and legal issues involved
... ›
September 28, 2020 - United States, Intellectual Property
Patent Drafting with James Mullen - GSAS Harvard Biotech Club & MoFo's Patent Course
By: Michael R. Ward
Morrison & Foerster LLP partner, founder and head of MoFo’s antibody IP practice James Mullen taught a class in patent drafting to members of the GSAS Harvard Biotech Club (HBC). This was the second of a six-part Patent Law Course offered by Morrison &
... ›
September 23, 2020 - Regulatory, Intellectual Property, Asia
China Patent Linkage Update: Codification and Rulemaking
On July 3, 2020, China’s National People’s Congress published the second draft of the latest amendment to China’s Patent Law (the “Draft Amendment”) for public comments, which were allowed to be submitted by August 16, 2020. The Draft Amendment included proposed revisions to 19
... ›
September 22, 2020 - Licensing + Commercial, United States, FDA, Startup, Data Analytics, Intellectual Property
GSAS Harvard Biotech Club and Morrison & Foerster’s Patent Course Off to a Roaring Start!
By: Michael R. Ward, Matthew Karlyn, Janet Xiao, Matthew A. Chivvis, Jie Zhou, Anna Yuan and Jillian A. Pesin-Fulop
More than 120 life sciences graduate students, post-docs and industry professionals attended the first class of a six part Patent Law Course offered by Morrison & Foerster and the GSAS Harvard Biotech Club on September 16, 2020. The Harvard Biotech Club is a student
... ›
September 09, 2020 - United States, FDA, Biotech, Healthcare, Pharma, Intellectual Property
Pediatric Exclusivity for Biologics
The U.S. Food and Drug Administration’s six-month pediatric exclusivity rules that apply to drugs also largely apply to biologics (albeit with certain distinctions), which may become a valuable life cycle management strategy for biopharmaceutical companies (hereinafter “Sponsors”) in addition to patent exclusionary rights. At
... ›
August 18, 2020 - United States, Litigation, Intellectual Property
Personalized Medicine Claims Get a Boost under New MPEP Revision
By: Meghan McLean Poon
The United States Patent and Trademark Office (USPTO) published the latest revision to its Manual of Patent Examining Procedure (MPEP) on June 30, 2020. According to the Executive Summary, in this revision, nearly all of the 27 chapters have been updated to incorporate new
... ›

Topic Archives: Intellectual Property

Podcast: Toward a Vaccine for COVID-19: The Science and Legal Considerations

By: Otis Littlefield and Michael R. Ward

Podcast: Applying AI and Data Science to the Fight Against COVID-19: The Science and Legal Considerations

By: Jean Nguyen, Kristen J. Mathews, Matthew Karlyn and Michael R. Ward

Podcast: Unpacking the Science and Legal Considerations of COVID-19 Testing

By: Matthew Karlyn, Kristen J. Mathews and Michael R. Ward

Navigating The CRISPR Patent Landscape and Understanding The FDA and its Process

By: Michael R. Ward

Special Patents and AI with Janet Xiao and Anna Yuan

By: Janet Xiao, Anna Yuan and Michael R. Ward

Patent Drafting with James Mullen - GSAS Harvard Biotech Club & MoFo's Patent Course

By: Michael R. Ward

China Patent Linkage Update: Codification and Rulemaking

GSAS Harvard Biotech Club and Morrison & Foerster’s Patent Course Off to a Roaring Start!

By: Michael R. Ward, Matthew Karlyn, Janet Xiao, Matthew A. Chivvis, Jie Zhou, Anna Yuan and Jillian A. Pesin-Fulop

Pediatric Exclusivity for Biologics

Personalized Medicine Claims Get a Boost under New MPEP Revision

By: Meghan McLean Poon